Akari Therapeutics Plc - American Depositary Shares (AKTX) analyst actions
Rating and price-target actions on AKTX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the AKTX overview →
1 measured AKTX analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial | Press release | +0.00% | -7.29% |
Keep exploring
More AKTX: earnings → · SEC filings → · AKTX overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| BioLineRx Ltd. - American Depositary Shares (BLRX) | 148 | -0.82% | 40% |
| INMED PHARMACEUTICALS (IMLFF) | 148 | 0.00% | 48% |
| BeyondSpring, Inc. - Ordinary Shares (BYSI) | 146 | 0.00% | 49% |
| Clearside Biomedical, Inc. (CLSD) | 145 | 0.00% | 46% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.